Anal

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, March 7, 2024
Neoplasm, Research, Toxicity, SCCA, FOLFIRINOX, Trifluridine/tipiracil, PR, Society, Breast, Health, Poster, Immunotherapy, Anal cancer, Pancreatic cancer, Fast Track, Anal, Progression-free survival, SITC, Pelareorep, Annual general meeting, Congress, Cancer, Gastrointestinal cancer, AB, International, Cohort, ESMO, Conference, Safety, TILS, Tumor microenvironment, Clinical trial, Survival, MOA, Oncology, Colorectal cancer, TIL, Blood, FDA, TSX, Thought, Pancreatic Cancer Action Network, Anal canal, PDAC, Patient, ONC, Pharmaceutical industry

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, March 7, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023.
  • General and administrative expenses for the fourth quarter of 2023 were $4.2 million, compared to $3.7 million for the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $4.7 million, compared to $4.8 million for the fourth quarter of 2022.
  • The net loss for the fourth quarter of 2023 was $3.9 million, compared to a net loss of $8.6 million for the fourth quarter of 2022.

Oramed Letter to Shareholders

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Senior, Letter, Joint venture, Investment, Marketing, FDA, Hemorrhoid, Note, Herpes labialis, Wart, JV, BMI, License, Patient, Pruritus ani, Anal, Body mass index, Failure, Glycated hemoglobin, Partnership, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.
  • I am pleased to share with you an update regarding Oramed.
  • Oramed and HTIT Joint Venture:
    In January 2024, Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture ("JV"), centered around Oramed's cutting-edge oral drug delivery technology.
  • We thank you for your support and look forward to keeping our shareholders updated on the important milestones ahead.

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Psyllium, Key, Inhalation, Committee, Monograph, Conjunctivitis, Inflammation, Pain, Bronchospasm, Anaphylaxis, Hemorrhoid, Human, Eye, Allergy, Date, Defecation, Risk, Seed, Mouth, Constipation, Safety, Stomach, Rectum, Plantago, Rhinitis, Patient, Medicine, Bleeding, Abdominal distension, Anal, Herbal medicine, Flatulence, Failure, Water

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Key, Inhalation, Committee, Monograph, Diet, Conjunctivitis, Inflammation, Pain, Bronchospasm, Anaphylaxis, Hemorrhoid, Human, Eye, Allergy, Date, Defecation, Risk, Seed, Mouth, Constipation, Hypercholesterolemia, Safety, Irritable bowel syndrome, Stomach, Rectum, Rhinitis, Abdominal pain, Patient, Medicine, Disease, Bleeding, Abdominal distension, Anal, Herbal medicine, Flatulence, Failure, Water

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

Retrieved on: 
Thursday, February 15, 2024
Neoplasm, Doctor of Philosophy, Immunotherapy, SCCA, News, Pharmaceutics, Destiny, PR, Optimism, Poster, Anal cancer, Pancreatic cancer, Anal, CEACAM6, Brigham and Women's Hospital, Bristol Myers Squibb, Therapy, Immune system, Pelareorep, International, Breast cancer, Fast track (FDA), Serology, AIO, Hospital, Hope, Principal investigator, HGG, Conference, Safety, Biomarker, Tumor microenvironment, Patent, Clinical trial, Survival, Harvard Medical School, Acute lymphoblastic leukemia, Injection, MSI, MD, BioNTech, FDA, TSX, Cancer, Entrepreneurship, Prevalence, American depositary receipt, Anal canal, Patient, Cone Health Women's Hospital, ONC, Pharmaceutical industry

According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."

Key Points: 
  • According to the American Association for Cancer Research "Cancer immunotherapeutics work by unleashing the power of a patient's immune system to fight cancer and, over the last decade, have emerged as one of the most exciting new approaches to cancer treatment."
  • Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is developing pelareorep, a unique immunotherapy with the power to awaken the immune system and unlock its antitumor potential.
  • It is committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
  • Bristol-Myers Squibb and Fate Therapeutics are some of the other key patent filers in cancer immunotherapy."

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Retrieved on: 
Wednesday, February 14, 2024
Anal, International, SAN, Breast cancer, Cetuximab, SCCA, TSX, AIO, Hope, E pluribus unum, Conference, PR, Symantec Endpoint Protection, Carcinoma, Lancet, PMID, SCAC, Anal canal, Patient, Optimism, Clinical trial, Poster, Anal cancer, Pancreatic cancer, ONC, Pharmaceutical industry

SAN DIEGO and CALGARY, Alberta, Feb. 14, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA). The study was expanded based on positive data from Stage 1 of the study, presented at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) in November 2023 (link to the PR, link to the poster).

Key Points: 
  • "These exciting clinical data, which exceed the Simon two-stage success criteria, provide strong support to expand the evaluation of pelareorep in patients with advanced anal cancer.
  • "We begin the Stage 2 expansion with substantial optimism for patients and the potential of pelareorep, especially considering the initial efficacy signal observed for pelareorep-based therapy in pancreatic cancer.
  • There is currently no established standard therapy for patients with anal carcinoma who have failed first-line treatment.
  • Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

Retrieved on: 
Wednesday, February 14, 2024
Anal, International, SAN, Breast cancer, Cetuximab, SCCA, TSX, AIO, Hope, E pluribus unum, Conference, PR, Symantec Endpoint Protection, Carcinoma, Lancet, PMID, SCAC, Anal canal, Patient, Optimism, Clinical trial, Poster, Anal cancer, Pancreatic cancer, ONC, Pharmaceutical industry

SAN DIEGO and CALGARY, Alberta, Feb. 14, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA). The study was expanded based on positive data from Stage 1 of the study, presented at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) in November 2023 (link to the PR, link to the poster).

Key Points: 
  • "These exciting clinical data, which exceed the Simon two-stage success criteria, provide strong support to expand the evaluation of pelareorep in patients with advanced anal cancer.
  • "We begin the Stage 2 expansion with substantial optimism for patients and the potential of pelareorep, especially considering the initial efficacy signal observed for pelareorep-based therapy in pancreatic cancer.
  • There is currently no established standard therapy for patients with anal carcinoma who have failed first-line treatment.
  • Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.

Bloop Announces Launch of Three Products for Anorectal Care

Retrieved on: 
Monday, November 13, 2023
Dicarboxylic acid, Woman, Customs officer, Oil, Carapa, Seed, Pharmacist, Body, Most, Patient, Hemorrhoid, Heart, Pain, Anal, Skin, OTC, Cosmetics, Bloop, Copaifera

PHILADELPHIA, Nov. 13, 2023 /PRNewswire-PRWeb/ -- Bloop announced today the launch of their direct-to-consumer website, GotBloop.com. Bloop, a new personal care consumer health products company, is leading the way in offering treatment for the body's most sensitive areas.

Key Points: 
  • Bloop, a new personal care consumer health products company, is leading the way in offering treatment for the body's most sensitive areas.
  • Bloop is proud to stand as an ally to the LGBTQ+ community, committed to fostering inclusivity and understanding in colorectal care.
  • Bloop offers three separate formulations, each specifically targeting one of these ailments: anal fissures , anal itch , or hemorrhoids .
  • Bloop produces maximum strength innovative products with natural and active ingredients, making them the best alternative to traditional OTC anorectal products.

Tavanta Therapeutics to Showcase Specialty Pipeline During the 2023 American Society of Clinical Oncology (ASCO) and American Society of Colon and Rectal Surgeons (ASCRS) Annual Congresses

Retrieved on: 
Wednesday, May 31, 2023
Dysphagia, Pharmacy, Metastasis, Abiraterone acetate, PDT, ASCRS, American Society of Colon and Rectal Surgeons, ASCO, American Society of Clinical Oncology, Anal, Patient, Alternative, Annual general meeting, Anal fissure, Poster, CDT, FDA, Therapy, Society, Potential, Pharmaceutical industry

"At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.

Key Points: 
  • "At ASCRS, we are excited to present the first data from our Phase 2 study of TAVT-119 in people with anal fissure.
  • Currently, non-surgical options to treat anal fissures include topical nitrates (which are limited by headache/tolerability) and topical calcium channel blockers (which are only available via compounding pharmacies as none are FDA-approved for anal fissure).
  • Based on the data that will be presented, we believe that TAVT-119 has the potential to offer patients a therapeutic option that is safe, efficacious and accessible."
  • "We are pleased to highlight these promising new data, which reflect the significant progress of our clinical development programs," said Lynne Powell, Chief Executive Officer of Tavanta Therapeutics.

Emmes Supports Groundbreaking Anal Cancer Study Sponsored by the National Cancer Institute

Retrieved on: 
Thursday, June 16, 2022
Industry, Public health, The New England Journal of Medicine, HIV/AIDS, Fortis Healthcare, Anal cancer, Risk, National Cancer Institute, Woman, Man, Cancer, Research, Subclinical infection, Adoption, UCSF, Biotechnology, USCF, Disease, Vaccination, MD, University, Health, Quality of life, AMC, HIV, History, Preventive healthcare, Incidence, Standard of care, Infection, Patient, University of California, San Francisco, Federation, Multimedia, Conference, Vulvar cancer, HSIL, HPV, Conference on Retroviruses and Opportunistic Infections, CRO, Anal, Pharmaceutical industry, Medicine, EMMS International

ROCKVILLE, Md., June 16, 2022 /PRNewswire/ -- Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that a team of its researchers contributed to a successful AIDS Malignancy Consortium (AMC) study. Results of the study, which demonstrated that treating and removing anal cancer precursor lesions reduced the cancer risk for HIV-infected men and women, were published in the New England Journal of Medicine. The Phase 3 trial results included 4,446 participants at 21 clinical sites across the U.S. and Puerto Rico.

Key Points: 
  • Results of the study , which demonstrated that treating and removing anal cancer precursor lesions reduced the cancer risk for HIV-infected men and women, were published in the New England Journal of Medicine.
  • The study enrolled people living with HIV aged 35 years and older who had at least one precursor lesion for anal cancer, called high-grade squamous intraepithelial lesions (HSIL).
  • According to Dr. Palefsky, "Anal cancer is the fourth most common cancer among people living with HIV.
  • For these individuals, the ANCHOR study shows for the first time that secondary prevention of anal cancer is possible through treatment of anal HSIL.